Subclinical Hyperthyroidism Enhances Gonadotropin‐Lowering Effects of Metformin in Postmenopausal Women
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.6144 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Robert Krysiak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland. Hauptthemen laut MEDLINE: Metformin, Postmenopause, Hyperthyroidism, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Metformin treatment decreases elevated concentrations of anterior pituitary hormones. The aim of this prospective, cohort study was to investigate whether hyperthyroidism modulates the impact of metformin on gonadotroph secretory function. The study population included 48 postmenopausal women with untreated type 2 diabetes or prediabetes, 24 of whom had coexisting grade 1 subclinical hyperthyroidism. Both groups were matched for age, insulin sensitivity, and gonadotropin levels. Over the entire study period, all participants were treated with metformin (2.55‐3 g daily). Plasma glucose, insulin, thyroid‐stimulating hormone (TSH), total and free thyroid hormones, follicle‐stimulating hormone (FSH), luteinizing hormone (LH), estradiol, prolactin, adrenocorticotropic hormone (ACTH), and insulin‐like growth factor‐1 (IGF‐1) were assayed at entry and 6 months later. At baseline, the study groups differed in levels of TSH and thyroid hormones but not in body mass index, blood pressure, glucose homeostasis markers (fasting glucose, homeostatic model assessment 1 of insulin resistance ratio [HOMA1‐IR], and glycated hemoglobin [HbA 1c ]), and the remaining hormones. There were no differences between both groups in the degree of reduction in plasma glucose and HbA 1c in response to metformin treatment. Although metformin decreased HOMA1‐IR in both groups, this effect was stronger in women with hyperthyroidism than with normal thyroid function (−50 ± 20% vs −30 ± 15%). Similar relationships were observed for FSH (−43 ± 21% vs −21 ± 12%). Only in hyperthyroid women did the drug reduce LH concentration (by 35 ± 17%). Metformin did not affect circulating levels of TSH, total and free thyroxine, total and free triiodothyronine, estradiol, prolactin, ACTH, and IGF‐1. The obtained results indicate that hyperthyroidism enhances the gonadotropin‐lowering effects of metformin, as well as the fact that this agent has a neutral effect on the hypothalamic–pituitary–thyroid axis in case of its overactivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
- Department of Pediatrics in Bytom, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
- Department of Pathophysiology, Faculty of Medicine, Academy of Silesia, Katowice, Poland.
ORCID-Profile: Robert Krysiak
Zitieren
APA
Krysiak, R., Kowalcze, K., & Okopień, B. (2025). Subclinical Hyperthyroidism Enhances Gonadotropin‐Lowering Effects of Metformin in Postmenopausal Women. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6144
Vancouver
Krysiak R, Kowalcze K, Okopień B. Subclinical Hyperthyroidism Enhances Gonadotropin‐Lowering Effects of Metformin in Postmenopausal Women. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6144
BibTeX
@article{Krysiak2025,
author = {Krysiak, Robert and Kowalcze, Karolina and Okopień, Bogusław},
title = {Subclinical Hyperthyroidism Enhances Gonadotropin‐Lowering Effects of Metformin in Postmenopausal Women},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.6144}
}
EUVIMED